About US
Contact us
-
Teva receives approval for generic Tribenzor in USTeva Pharmaceutical Industries has secured approval for generic Tribenzor(olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the US and is in the last stages of launch preparation.2016/11/17
-
University of Adelaide researchers test drug that promises to prevent pre-term birthResearchers at the University of Adelaide have conducted a successful drug test that shows early promises of preventing pre-term birth. This success will help to understand the inflammatory mechanism2016/11/16
-
NICE recommends treatment with 60mg of ticagrelor in post-heart attack patientsAstraZeneca has announced that National Institute of Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending 60mg of ticagrelor with aspirin for anti-clottin2016/11/16
-
Brexit battle heats up over winning EMA from LondonA long list of EU countries would love to behometo the European Medicines Agency (EMA) post-Brexit--France, Italy, Denmark, Sweden, Hungary and more. But the U.K. is not going to let it go without put2016/11/15
-
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's KeytrudaThursday was quite the day for Bristol-Myers Squibb’s Opdivo. After becoming the first med to succeed in a Phase III gastric cancer trial, the drug nabbed anFDA approvalin head-and-neck cancer--and ev2016/11/15
-
UPDATED: Gilead snags FDA approval for improved hep B drug VemlidyGilead Sciences, whose hepatitis C dynasty has been slipping, haswon approvalfor its next-gen hepatitis B treatment. The Foster City, CA-based drugmaker said Thursday that the FDA had approvedVemlidy2016/11/14
-
DOJ's price-fixing investigation could lead to sizable liabilities, analyst saysWhile industry closely tracks developments on the Department of Justice price-fixing investigation into a host of generics companies, one influential analyst has run the numbers on potential liabiliti2016/11/14
-
UPDATED: FDA's new citizen petition rules remove speed bumps for generic, biosim approvalsBranded drugmakers may have one less tool to delay generic competitors--and, crucially, biosimilar versions of some of the industry's top-selling products--with Tuesday’s decision by the FDA to amend2016/11/11
-
Senators seek FTC probe of Mylan's EpiPen practicesMonths into a bruising EpiPen pricing scandal, congressional scrutiny on Mylan continues to heat up. Top members of the Senate Judiciary Committee havecalled onthe Federal Trade Commission to examine2016/11/11
-
Already facing $200M in damages, J&J seeks to move talc cases out of St. LouisLooking to rebound from three talc case defeats in St. Louis totaling nearly $200 million in damages, Johnson & Johnson is petitioning for a change of venue. The New Jersey drugmaker will argue2016/11/10